# US 2016/0250280 A1 · Uses Of Cyclic Peptides For Treating And Preventing Atherosclerosis Uses of Cyclic Peptides for Treating and Preventing Atherosclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250280 A1
- Document ID: US20160250280A1
- Status: Published application
- Kind: A1
- Application number: 14/781,859
- Filed: 2014-04-02
- Published: 2016-09-01
- Earliest claimed: 2013-04-02
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: M. Reza GHADIRI; Luke J. LEMAN; Yannan ZHAO; Bruce E. MARYANOFF
- Web page: https://patentgrep.com/patent/US20160250280A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides cyclic compounds that are useful in preventing or treating atherosclerosis or related disorders. The invention also provides therapeutic methods for treating or preventing various diseases or disorders associated with or mediated by atherosclerosis. Further provided in the invention are methods of screening for anti-atherosclerotic cyclic peptides with improved properties.

## Claims

### Claim 1

A method for treating or preventing atherosclerosis or a disorder associated with or mediated by atherosclerosis, comprising administering to a subject afflicted with or at risk of developing atherosclerosis, or a disorder associated with or mediated by atherosclerosis, a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a cyclic peptide having a sequence of from four to about sixteen amino acid residues or analogs thereof, which are alternating D- and L-residues along partial or entire sequence of the peptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is afflicted with or at risk of developing hypercholesterolemia, a cardiovascular disorder, an atherosclerotic vascular disease, a cerebrovascular disease, aneurysm, a peripheral vascular disease or intermittent claudication.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the cyclic peptide compound has a sequence formula of c[B-J-U1-X-U2-Z],
wherein B is a peptide segment comprising at least 2 hydrophobic amino acid residues or analogs thereof; J comprises a positively charged amino acid residue, a polar uncharged amino acid residue, or an analog thereof; one or both of U1 and U2 comprise a negatively charged amino acid residue, a polar uncharged amino acid residue or analog thereof; X comprises a polar uncharged amino acid residue, a His residue or an analog thereof; and Z comprises Asn, Gln, a charged amino acid residue, or an analog thereof; and
wherein amino acid residues or analogs of the cyclic peptide are alternating D- and L-residues along the entire sequence of the cyclic peptide.

### Claim 6 (depends on 5)

The method of claim 5, wherein B consists of 2, 3, 4, 5, 6, or 7 hydrophobic amino acid residues or analogs thereof.

### Claim 7 (depends on 5)

The method of claim 5, wherein B consists of 3 hydrophobic amino acid residues or analogs thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein B consists of DTrp-Leu-DTrp, DTyr-Leu-DTyr, DTrp-DTrp, DPhe-Leu-DTrp, Trp-DLeu-Trp, Tyr-DLeu-Tyr, Trp-DTrp-Trp, or Phe-DLeu-Trp.

### Claim 9 (depends on 5)

The method of claim 5, wherein J is Lys, Arg, Ser, His, Orn (ornithine), diaminobutyric acid or diaminopropionic acid.

### Claim 10 (depends on 5)

The method of claim 5, wherein J is naphthylalanine (Nal), homoleucine (Hml), or 2-amino-octanoic acid (Aoc).

### Claim 11 (depends on 5)

The method of claim 5, wherein U1 and U2 are each independently a DAsp, DGlu or DSer residue.

### Claim 12 (depends on 5)

The method of claim 5, wherein X is Asn or Gln.

### Claim 13 (depends on 5)

The method of claim 5, wherein Z is a positively charged residue.

### Claim 14 (depends on 13)

The method of claim 13, wherein Z is a Lys, Arg, His, Orn (ornithine) or diaminobutyric acid.

### Claim 15 (depends on 5)

The method of claim 5, wherein B consists of DTrp-Leu-DTrp or DTyr-Leu-DTyr; J is Lys, Arg, or Ser; U1 and U2 are each independently a DAsp, DGlu or DSer residue; X is Asn or Gln; and Z is Lys, Arg, Orn (ornithine) or diaminobutyric acid.

### Claim 16 (depends on 5)

The method of claim 5, wherein the cyclic peptide is selected from the group consisting of c[wLwReQeR] (SEQ ID NO:1), c[wLwKdQeK] (SEQ ID NO:2), c[wLwRdQeK] (SEQ ID NO:3), c[wLwSeQsO] (SEQ ID NO:4), c[fWwYqHhQ] (SEQ ID NO:5), c[LwLwLrKe] (SEQ ID NO:6), c[wLwZeQeK] (SEQ ID NO:7), c[wLwKdNdK] (SEQ ID NO:8), c[wLwRdNdK] (SEQ ID NO:9), c[wLwKdQdK] (SEQ ID NO:10), c[wLwKeNeK] (SEQ ID NO:11), c[wLwHeNeK] (SEQ ID NO:12), c[wLwOeQeO] (SEQ ID NO:13), c[wLMewSeQMesO] (SEQ ID NO:14), and c[wLwOeNeO] (SEQ ID NO:19), c[w(Aoc)wSeQsO] (SEQ ID NO:22), c[wLwReNeO] (SEQ ID NO:23), c[wLwHeQeH] (SEQ ID NO:24), c[yWyKsHaE] (SEQ ID NO:25), c[wLlwKdDk] (SEQ ID NO:26), c[w(Nal)wReQeR] (SEQ ID NO:28), c[w(Hml)wReQeR] (SEQ ID NO:29), and c[wLwSeQhK] (SEQ ID NO:40).

### Claim 17 (depends on 5)

The method of claim 5, wherein the cyclic peptide comprises a sequence of c[wLwReQeR] (SEQ ID NO:1), c[wLwSeQsO] (SEQ ID NO:4), or c[wLwSeQhK] (SEQ ID NO:40).

### Claim 18 (depends on 1)

The method of claim 1, wherein the cyclic peptide compound has a sequence formula of c[wLw-J-u1-X-u2-Z] and comprises about 8 alternating D- and L-form of amino acid residues or amino acid analogs, wherein “wLw” denotes a tripeptide segment consisting of DTrp-Leu-DTrp; J is serine or a positively charged amino acid residue or analog; u1 and u2 are each independently a DAsp, DGlu or DSer residue; X is Asn residue or Gln residue; and Z is a positively charged amino acid residue or analog.

### Claim 19 (depends on 18)

The method of claim 18, wherein J is Lys, Arg, His, Ser, Orn (ornithine), diaminobutyric acid or diaminopropionic acid.

### Claim 20 (depends on 18)

The method of claim 18, wherein Z is Lys, Arg, or Orn (ornithine).

### Claim 21 (depends on 18)

The method of claim 18, wherein the cyclic peptide is selected from the group consisting of c[wLwReQeR] (SEQ ID NO:1), c[wLwKdQeK] (SEQ ID NO:2), c[wLwRdQeK] (SEQ ID NO:3), c[wLwSeQsO] (SEQ ID NO:4), c[wLwZeQeK] (SEQ ID NO:7), c[wLwKdNdK] (SEQ ID NO:8), c[wLwRdNdK] (SEQ ID NO:9), c[wLwKdQdK] (SEQ ID NO:10), c[wLwKeNeK] (SEQ ID NO:11), c[wLwHeNeK] (SEQ ID NO:12), c[wLwOeQeO] (SEQ ID NO:13), and c[wLwOeNeO] (SEQ ID NO:19).

### Claim 22 (depends on 1)

The method of claim 1, wherein the cyclic peptide is selected from the group consisting of c[fWwYqHhQ] (SEQ ID NO:5), c[(Me)wLwR(Me)eQeR] (SEQ ID NO:46), c[WlWwkhkh] (SEQ ID NO:47), c[wFyYhOrS] (SEQ ID NO:48), c[(PA)wLlHsKk] (SEQ ID NO:49), c[WIWrEqEr] (SEQ ID NO:50), c[fWwYtRhS (SEQ ID NO:51)], c[wFfYrHhS] (SEQ ID NO:52), and c[wLwKhShK] (SEQ ID NO:53).

### Claim at position 22

23-24. (canceled)

### Claim 25

A use of a cyclic peptide having a sequence of from four to about sixteen amino acid residues or analogs thereof, which are alternating D- and L-residues along partial or entire sequence of the peptide, in an amount effective to treat or prevent atherosclerosis or a disorder associated with or mediated by atherosclerosis in a subject.

### Claim 26 (depends on 25)

The use of claim 25, wherein the cyclic peptide compound has a sequence formula of c[B-J-U1-X-U2-Z], wherein B is a peptide segment comprising at least 2 hydrophobic amino acid residues or analogs thereof; J comprises a positively charged amino acid residue, a polar uncharged amino acid residue, or an analog thereof; one or both of U1 and U2 comprise a negatively charged amino acid residue, a polar uncharged amino acid residue or analog thereof; X comprises a polar uncharged amino acid residue, a His residue or an analog thereof; and Z comprises Asn, Gln, a charged amino acid residue, or an analog thereof; and wherein amino acid residues or analogs of the cyclic peptide are alternating D- and L-residues along the entire sequence of the cyclic peptide.
